#AgileLeaders on Biologics and the future of Antibodies

In this #AgileLeaders Forum we will be discussing the Biologics for Medicines sector with a special focus on the future of Antibodies drug discovery and development. Chatham House Rules apply.

The biologics sector, encompassing monoclonal antibodies (mAbs), vaccines, and gene therapies, is a cornerstone of modern medicine, projected to expand from around $444-522 billion in 2024-2026 to $827-1,127 billion by 2034. .Driven by chronic diseases like cancer and autoimmune disorders, oncology holds a dominant 28-30% share, with mAbs commanding 57% of the market due to their precision in targeting diseases.

Future of Antibodies in Drug Discovery

Antibodies are evolving rapidly, with next-generation formats like bispecific antibodies (BsAbs), multi-specific antibodies (MsAbs) and antibody-drug conjugates (ADCs), and engineered constructs leading innovation. BsAbs, enabling dual targeting for enhanced efficacy in immuno-oncology and autoimmune diseases, are forecasted to surge in development, bolstered by technologies like knob-into-hole and CrossMab for stability and tumor penetration. ADCs, combining antibodies with cytotoxic payloads, are expanding beyond oncology to autoimmune and infectious diseases, estimated to grow significantly (double in 5 years). The next-generation antibody market, valued at $50 billion in 2025, could reach $150 billion by 2033 via improved specificity, reduced immunogenicity, and personalized medicine.

Regional leaders like North Americ fuel this through R&D investments and regulatory support, with Asia-Pacific emerging fast. Challenges include manufacturing scalability, with in-house and outsourced models, plus biosimilars, promise accessibility. By 2034, antibodies will redefine drug development with AI-driven discovery and multi-specific platforms.

At our Agile Leaders Forum we will have experts to discuss the future of antibodies specifically, along with our participating audience, to get to know where the UK stands in the global market. Many antibodies used in medicines were first discovetred and developed in the UK, so it will be interesting to discuss where the UK stands now in the global market, and how we can work with Chinese development partners to derisk and reduce costs, and remaining competative.

How you will benefit from attending Agile Leaders?

As a Business or Research Leader, you will benefit from this "Agile" workshop by sharing common challenges and building deeper connections and trust with your peers. In turn, the aim is to build your confidence when working in areas normally outside your comfort zone, by learning and having discussions with this / your "Agile" peer network. You can speak to people in a similar position about issues you may not have the opportunity to discuss elsewhere. You can discuss your challenges with a view of learning from other people's experiences to help you find a solution or spark an idea. Why let leaders of emerging companies re-invent the wheel to be successful when we can learn from the experiences of others who have faced similar challenges before.

Chatham House Rules apply - "what goes on in the workshop, stays in the workshop - so to speak!" We are planning to write up some of the interesting features of the discussion but won't attribute anyone's comment or view so they can be identified. This is so we feel we can a free and open discussion without the worry about being quoted somewhere.

Our mission is to help you build your innovation enabled healthcare business so it is "fit for purpose," truly innovative and attractive to the global markets. Helping you build solid trustworthy networks with your peer group, and help spread your creative R&D business network nationally and internationally. Our motivation and focus is on helping you build long-term trustworthy business relationships and support you on your journey through our supportive business community.

This workshop is facilitated by Prof Tony Sedgwick, the self-professed www.ThoughtDisruptor.com. Tony has an esteemed career in life sciences in academia and in business, he is a trained pathologist. His accolades include once being the Global Head of Clinical Trials at Roche AG, and he has also been CEO of four life science companies, Chairman of over 10 Companies, and many positions within the academic community. He is also an active psychologist which is helping him develop his "Agile" community group development passion and is a Jiu-Jitsu Grand Master VI. Last year Tony published the book "The Mighty Advisor" which was a number 1 best seller in the Amazon STEM Business Management category.

We will start this Agile Leaders Forum on the 22 April with a 1.30 pm arrival time (with a prompt 2.00 pm start for the discussion). We are in the Council Chambers in Victoria House in Central London inbetween Holborun and Tottenham Court Road Tube Stations.

For this event, we are limiting it to a maximum of 50 Life Science Leaders of future life science leaders only. As such, we recommend you book as soon as possible to avoid disappointment.

Our promise to you is our Agile Leaders Forum will be like no other business workshop you have experienced. You will be walking out of the session inspired, educated and more connected.

In summary:

1.30 pm - the majority of participants arrive:

2 pm - Kick off with keynote interview.

2.15 pm - The interviews with listed keynotes and Axcelead team - wider outreach to participants to also "sense and feel" their opinions on the keynotes and what they have heard. What are the most common challenges amongst participants etc?

3.30 pm - coffee & tea break

4-4.20 pm Axcelead presentation

4.20-5.30 pm - Further feedback from all the participants

5.30 pm End

FEE = £60 - ALL-INCLUSIVE - LIMITED TO 50 x C-Level Leaders or Research Directors of R&D Innovation companies or aspiring future leaders.

WuXi Biologics is a leading global CRDMO, with the R represented by our premium-quality CRO Services. With expertise in diverse drug modalities, we deliver comprehensive research services, including antibody discovery, protein production and engineering, and in vitro/in vivo testing, to seamlessly advance our clients’ molecules from concept to CMC development.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher Graham Combe